Every AXLRx Alzheimer's Disease report, across 4 report types. Each is scoped to your asset and verified to a live source.
Lecanemab versus donanemab in early AD. CMS amyloid-confirmation coverage and ARIA monitoring as the access gate.
US Alzheimer's staging, the amyloid-confirmation diagnostic pathway, and the FDA-cleared plasma pTau-217 blood test resizing the addressable pool.
Why CMS's coverage-with-evidence-development registry, not IRA negotiation, is the anti-amyloid access gate, plus ICER's below-value verdict and Part B routing.
Two anti-amyloid agents already sit inside CMS's coverage-with-evidence-development registry. A new entrant inherits that gate and must price inside ICER's benchmark to avoid Aduhelm's fate.
AXLRx publishes Competitive Intelligence, Disease Landscape, Payer & HTA, and Launch Readiness for Alzheimer's Disease. Each report is scoped to your asset, verified to a live source, and delivered in 72 hours.
Current Alzheimer's Disease coverage spans United States. Additional markets can be commissioned against the same evidence standard.
Every figure is cited to a live source at the point of writing and re-checked in an independent audit pass. The latest Alzheimer's Disease reports were updated July 2026.